Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) EPS (Basic): 2016-2025

Historic EPS (Basic) for UroGen Pharma (URGN) over the last 10 years, with Sep 2025 value amounting to -$0.69.

  • UroGen Pharma's EPS (Basic) fell 35.29% to -$0.69 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.46, marking a year-over-year decrease of 18.49%. This contributed to the annual value of -$2.96 for FY2024, which is 16.62% up from last year.
  • As of Q3 2025, UroGen Pharma's EPS (Basic) stood at -$0.69, which was up 34.29% from -$1.05 recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's EPS (Basic) registered a high of -$0.51 during Q3 2024, and its lowest value of -$1.35 during Q3 2021.
  • Over the past 3 years, UroGen Pharma's median EPS (Basic) value was -$0.82 (recorded in 2024), while the average stood at -$0.85.
  • Per our database at Business Quant, UroGen Pharma's EPS (Basic) soared by 42.40% in 2023 and then plummeted by 35.29% in 2025.
  • UroGen Pharma's EPS (Basic) (Quarterly) stood at -$1.27 in 2021, then climbed by 1.57% to -$1.25 in 2022, then surged by 42.40% to -$0.72 in 2023, then dropped by 11.11% to -$0.80 in 2024, then plummeted by 35.29% to -$0.69 in 2025.
  • Its last three reported values are -$0.69 in Q3 2025, -$1.05 for Q2 2025, and -$0.92 during Q1 2025.